Malaria & Tropical Disease Research — Human Serum AB for Plasmodium falciparum Culture
Plasmodium falciparum in vitro culture is the cornerstone of malaria drug discovery, vaccine development, and parasite biology research. The Trager and Jensen protocol (1976) established human red blood cells and human serum as the required culture components — and this remains the standard today. SeamlessBio supplies Human Serum Type AB OTC for Plasmodium culture and Human Serum AB Heat Inactivated for PBMC-based immunological assays.
Human Serum AB OTC — Plasmodium Culture
The published standard (Trager & Jensen 1976) for continuous P. falciparum culture. AB type — no RBC agglutination. Native OTC — complement intact for natural growth conditions. 5% in RPMI-1640.
Human Serum AB HI — PBMC Assays
For PBMC-based malaria immunology: ELISpot, cytokine assays, proliferation. Heat inactivated (56°C/30 min) eliminates complement-mediated PBMC lysis during antigen stimulation.
BSA Low Endotoxin — AlbuMAX Alternative
BSA Low Endotoxin as base for AlbuMAX-equivalent serum-free P. falciparum culture. Used with lipid supplement at 0.5% equivalent concentration for defined conditions.
Lot Reservation — Full Campaign Coverage
Sorbitol synchronisation of P. falciparum requires 4–8 weeks of continuous culture in the same serum lot. SeamlessBio reserves dedicated lots for malaria research at no cost during the evaluation phase.
AlbuMAX vs Human Serum AB — when to use which
AlbuMAX (lipid-enriched BSA) supports P. falciparum growth and is used when defined serum-free conditions are required. However, Human Serum AB OTC remains the gold standard for parasitological assays where physiological serum conditions are important.
For drug susceptibility testing (DISA, RSA), Human Serum AB OTC is specifically required: human serum protein binding of antimalarial compounds (chloroquine, artemisinin, lumefantrine) is physiologically relevant. AlbuMAX underestimates protein binding and overestimates free drug concentration — leading to systematic errors in IC50 determination.
For routine passaging where defined conditions are acceptable and cost is the primary constraint, AlbuMAX provides lower lot-to-lot variability at lower cost. For assays that generate data for regulatory submissions or publication, Human Serum AB OTC is the appropriate choice.
Lot reservation is essential for malaria research: P. falciparum synchronisation by sorbitol requires 4–8 weeks of continuous culture. A serum lot change mid-synchronisation disrupts parasite growth kinetics, invalidates synchrony, and requires restarting from frozen stocks. SeamlessBio holds reserved lots at no cost during the evaluation phase.
Recommended products
- Human Serum AB OTC — P. falciparum culture, drug susceptibility
- Human Serum AB OTC Male — hormone-free, consistent OPKA
- Human Serum AB HI — PBMC ELISpot, malaria immunology
- BSA Low Endotoxin — AlbuMAX-equivalent base, lipid supplement
- Guinea Pig Serum — Complement fixation tests (CFT) — tropical disease serology
- FBS Low Endotoxin — Leishmania, Trypanosoma, Toxoplasma culture
Standard Protocol — Plasmodium falciparum Continuous Culture
| Parameter | Specification |
|---|---|
| Base medium | RPMI-1640 + 25 mM HEPES + 0.2% NaHCO₃ |
| Serum supplement | 5% Human Serum Type AB OTC (Trager & Jensen standard) |
| RBC source | Type O+ human erythrocytes — 2–5% haematocrit |
| Atmosphere | 5% CO₂ / 5% O₂ / 90% N₂ (candle jar or controlled gas mixture) |
| Temperature | 37°C |
| Serum alternative | AlbuMAX I or II (lipid-rich BSA) — serum-free option for defined conditions |
Full Application Portfolio — Malaria & Tropical Disease Research
| Application | Recommended Product | Protocol Note |
|---|---|---|
| P. falciparum continuous culture | Human Serum AB OTC native — 5% | Trager & Jensen protocol. Native complement intact. AB type — no RBC lysis. |
| Drug susceptibility assay (RSA, DISA) | Human Serum AB OTC — 5% | Human serum protein binding of antimalarials is physiologically relevant. AlbuMAX overestimates free drug. |
| PBMC stimulation — malaria antigens | Human Serum AB HI — 5–10% | HI eliminates complement-mediated PBMC lysis during antigen stimulation. |
| IFN-γ ELISpot — vaccine immunogenicity | Human Serum AB HI or FBS VLE ≤1 EU/mL | Human Serum AB HI provides species-matched matrix for T cell responses to malaria antigens (RTS,S, R21). |
| Opsonophagocytosis (OPKA) | Human Serum AB OTC native — 10–25% | Active human complement required. Human IgG + complement for physiological opsonisation of P. falciparum-infected RBCs. |
| Leishmania / Trypanosoma culture | FBS Low Endotoxin ≤5 EU/mL — 10–20% | SDM-79 (Leishmania), HMI-9 (Trypanosoma). Low Endotoxin reduces non-specific innate immune activation. |
| Toxoplasma gondii infection assay | FBS Low Endotoxin ≤5 EU/mL — 10% | HFF or Vero host cells. Low Endotoxin reduces background cytokine in macrophage infection models. |
| Complement fixation test (CFT) | Guinea Pig Serum | Standard complement source for tropical disease serology — Brucella, Leishmania, Trypanosoma CFT diagnostics. |
Human Serum AB OTC vs AlbuMAX — Comparison
| Parameter | Human Serum AB OTC | AlbuMAX I/II |
|---|---|---|
| Physiological relevance | ✅ Native human serum — closest to in vivo conditions | Lipid-enriched BSA — defined but non-physiological |
| Drug susceptibility testing | ✅ Correct protein binding of antimalarials | Overestimates free drug — underestimates protein binding |
| Lot-to-lot variability | Pooled donors — batch reservation minimises impact | Lower variability — defined composition |
| Complement activity | Active — relevant for some invasion and OPKA assays | No complement activity |
| Cost | Higher | Lower for routine passaging |
| Published standard | ✅ Trager & Jensen 1976 — WHO malaria reference protocol | Alternative — widely used for routine passaging |
Frequently Asked Questions
Related Applications & Products
Lot Reservation for Malaria Research Programmes
Human Serum AB OTC lot reservation — 6-week no-cost hold. Viral testing documentation (HIV, HBV, HCV, CMV, EBV, PVB19) per lot on request.
Email: info@seamlessbio.de | +49 851 37932226
